Table 2.
Safety and tolerability in patients with and without prior axitinib treatment.
| AE | Prior axitinib | No prior axitinib |
|---|---|---|
| Treatment-related AE | 84.5% | 92.3% |
| Reduction due to AE | 28.0% | 29.7% |
| Interruption due to AE | 53.5% | 53.8% |
| Discontinuation due to AE | 25.6% | 19.8% |
Abbreviation: AE, adverse event.